Naturally activated adaptive immunity in COVID-19 patients

Xiaofang Yang | Tongxin Dai | Xiaobo Zhou | Hongbo Qian | Rui Guo | Lei Lei | Xingzhe Zhang | Dan Zhang | Lin Shi | Yanbin Cheng | Jinsong Hu | Yaling Guo | Baojun Zhang

1Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China
2Department of Clinical Laboratory, The 8th hospital of Xi'an, Xi'an, Shaanxi, China
3Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China
4Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China
5Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, Shaanxi, China
6Institute of infection and immunity, Translational Medicine Institute, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China
7Basic and Translational Research Laboratory of Immune Related Diseases, Xi'an, Shaanxi, China

Correspondence
Jinsong Hu, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China. Email: jinsong.hu@xjtu.edu.cn
Yaling Guo, Department of Clinical Laboratory, The 8th hospital of Xi'an, Xi'an, Shaanxi, 710016 China. Email: 15102915638@126.com
Baojun Zhang, Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China. Email: bj.zhang@mail.xjtu.edu.cn

Funding information
This work was supported by grants from Natural Science Foundation of China (No. 81820108017), National Natural Science Foundation of China (No. 81771673), COVID-19 special project of Xi'an Jiaotong University Foundation (No. xxy032020002), COVID-19 special project funded by Qinnong Bank and Xi'an Jiaotong University (No. 01), Project funded by China Postdoctoral Science Foundation (No. 2019M653673) and Opening Project of Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University (No. 2019LHM-KFKT003). We thank all the doctors, nurses, public health workers and patients for their contribution against SARS-CoV-2 infection.

Abstract
Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) has rapidly spread worldwide, threatening the health and lives of many people. Unfortunately, information regarding the immunological characteristics of COVID-19 patients remains limited. Herein, we collected blood samples from 18 healthy donors (HDs) and 38 COVID-19 patients to analyse changes in the adaptive immune cell populations and their phenotypes. We observed that the lymphocyte percentage moderately decreased, CD4 and CD8 T cell percentage among lymphocytes were similar, and B cell percentage was increased in COVID-19 patients in comparison to that in HDs. T cells, especially CD8 T cells, showed an enhanced expression of late activation marker CD25 and exhaustion marker PD-1. Importantly, SARS-CoV-2 infection increased the percentage of T follicular helper– and germinal centre B–like cells in the blood. The parameters in COVID-19 patients remained unchanged across various age groups. Therefore, we demonstrated that the T and B cells are activated naturally and are functional during SARS-CoV-2 infection. These data provide evidence that the adaptive immunity in most patients could be primed to induce a significant immune response against SARS-CoV-2 infection upon receiving standard medical care.

KEYWORDS
adaptive immunity, COVID-19, lymphocyte, SARS-CoV-2
A severe pneumonia-associated respiratory syndrome began in Wuhan, China, in December 2019, which was subsequently declared as a public health emergency of international concern by WHO. The novel coronavirus strain was officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\textsuperscript{1,2} Coronavirus infections, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), can cause severe respiratory diseases.\textsuperscript{3,4} SARS-CoV-2 is an enveloped positive-strand RNA virus, which belongs to the same family as SARS-CoV and MERS-CoV based on genome similarity, Coronavirusidae.\textsuperscript{5-7}

A number of studies have demonstrated that the adaptive immunity responds to coronavirus infections and is required for efficient clearance of the virus. In patients infected with SARS-CoV, the acute phase of infection is associated with a severe reduction in T cell numbers in the blood, involving a dramatic loss of CD4 and CD8 T cells in comparison to healthy control individuals.\textsuperscript{8,9} This suggests that SARS-CoV infection impairs cellular immunity in the early stages of the disease. With the prolonged recovery time of SARS-infected patients, expression of activated T cell markers, such as CD69 and CD25, decreases,\textsuperscript{10,11} indicating that T cell activation in response to the virus is impaired.\textsuperscript{12} With the improvement of the disease, the ratio of CD4 to CD8 T cells increases, indicating that CD4 T cells recover faster than CD8 T cells.\textsuperscript{13} In addition, out of the 92% of cured SARS patients whose B cells initially declined and then increased or continued to increase during the course of the disease, only 8% had a constant or decreasing cell count.\textsuperscript{14} Similar to SARS patients, leukopenia and lymphopenia are also observed in MERS patients, albeit to a lesser degree than that observed in SARS patients. A clinical study showed that 14% of MERS patients had leukopenia, while 34% of the patients had lymphopenia.\textsuperscript{15} MERS-CoV-infected patients that exhibited distinctively high frequencies of MERS coronavirus–reactive CD8 T cells were associated with severe/moderate illness, whereas CD4 T cell response was minimally detected at this stage. In the convalescent phase, a moderate increase in CD4 T cells was detected.\textsuperscript{15}

Currently, very few studies have reported that COVID-19 patients develop lymphopenia and exhibit an increase in pro-inflammatory cytokines in severe condition.\textsuperscript{16-18} The information on changes in immune cells and their functions in response to SARS-CoV-2 infection is still very limited. Based on the fact that T and B cells respond to infections and play critical roles in defending against virus infections, a systematic study on the changes in T and B cells in COVID-19 patients will help uncover the immune response against SARS-CoV-2 infection and will also provide insights for COVID-19 diagnosis and treatment.

A new study showed that people infected with beta-coronaviruses including SARS-CoV and MERS could establish T cell immunity to nucleocapsid protein (NP).\textsuperscript{19} The analysis of blood samples of 14 COVID-19 patients displayed a strong correlation between neutralization antibody titres and the numbers of virus-specific T cells.\textsuperscript{20} Wen et al reported that during the recovery stage of COVID-19, plasma cells underwent a significant increase, whereas naïve B cells decreased remarkably.\textsuperscript{21} Several studies reported that SARS-CoV-2 elicits a robust B cell response, as evidenced by the detection of virus-specific IgM, IgA and neutralizing IgG antibodies (nAbs) in the days following infection.\textsuperscript{20,22} Importantly, Zost and colleagues identified several human monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein, which exhibited potent neutralizing activity and fully blocked the receptor-binding domain of S (SRBD) from interacting with human ACE2 (hACE2).\textsuperscript{23} In addition, two of the most potently ACE2 blocking mAbs have been proven to protect rhesus macaques from SARS-CoV-2 infection.\textsuperscript{23} However, further studies will be required to identify, design and synthesize antibodies and drugs targeting SARS-CoV-2.

In this study, we analysed the blood samples from 18 healthy donors (HDs) and 38 patients and focused on the characterization of adaptive immune cell populations and their phenotypes upon SARS-CoV-2 infection. We showed that upon infection, lymphocyte percentage declined, CD4 and CD8 T cells percentage within the lymphocyte population remained unchanged, and B cell percentage was relatively increased. CD4 and CD8 T cells exhibited a mild and strong activation phenotype. Notably, the percentage of T follicular helper (Tfh)– and germinal centre B–like (GCB-like) cells increased. Similar phenotypes among the patients in various age groups indicate that aged individuals are also capable of responding to SARS-CoV-2 infection. Our data support the notion that adaptive immunity could be normally activated, and it could defend against SARS-CoV-2 infection.
anti-human CD4 (OKT4), PerCP/Cyanine5.5 anti-human CD8 (SK1), APC anti-human CD19 (HIB19), APC anti-human CD25 (BC96), PE anti-human CD69 (FN50), PE anti-human CD185 (CXR5) (J252D4), PE anti-human CD183 (CXR3) (G025H7), APC anti-human CD279 (PD-1) (EH12.2H7), PE anti-human CD95 (Fas) (DX2), PE anti-human CD127 (A019D5), APC/Cyanine7 anti-human CD45RA (HI100), PE/Cy5 anti-human CD45RO (UCHL1), PE anti-human CD95 (Fas) (DX2) and FITC antimouse/human GL7 Antigen (GL7). They were purchased from BioLegend. Blood cells were stained with Abs in the dark at room temperature for 15 minutes and analysed on a FACSCanto II flow cytometer (BD Biosciences). FlowJo 8 was used for data analysis.

2.4 Statistical analysis

The continuous variable of normal distribution is represented by mean ± standard deviation, the non-normal distribution is represented by median [IQR], and the classified variable is represented by count (percentage). Student’s t test was performed for two group analysis using SPSS 22.0 software. * and ** stand for P<0.05 and P<0.01, respectively.

3 RESULTS

3.1 The percentage analysis of T and B cells in COVID-19 patients

To determine the change in the composition of adaptive immune cells, we compared the percentage of T and B cells in the blood samples from HDs and COVID-19 patients using flow cytometry.

| TABLE 1 Characteristic analysis of COVID-19 patients and healthy donors |
|---------------------------------------------------------------|
| **Sample information**                                         |
|                                                               |
| **Gender** | **Age** |
|-----------------------------------|---------|
| **HD**| 9/18, 50% | 39.06 ± 4.26 |
| **Patients** | 23/38, 60.53% | 45.08 ± 4.06 |

Lymphocyte percentage in the whole blood was not significantly different between HDs and COVID-19 patients, though it exhibited a decreasing trend in the patients (Figure 1A). Within the lymphocyte population, the percentages of CD4+ and CD8+ T cells were comparable (Figure 1B and C), whereas B cell percentage was significantly increased (Figure 1D) in COVID-19 patients.

3.2 An activated phenotype of T cells in COVID-19 patients

To evaluate the T cell status in response to SARS-CoV-2 infection, we analysed the expression of CD69, CD25, PD-1, CD45RA, CD45RO and CXCR3 in both CD4+ and CD8+ T cells. In CD4+ T cells of the COVID-19 patients, the expression of CD69 and CD25 (Figure 2A and B) and the percentage of regulatory T cells, marked by CD3+CD4+CD25+CD127- (Figure 2F), were similar to that of HDs. CD25 expression was significantly up-regulated in CD8+ T cell population of the patients (Figure 3B). The proportion of naive and effector/memory cells in both CD4+ T cells (Figure 2D and E) and CD8+ T cells (Figure 2E and F) of the two groups were not significantly different. PD-1 expression was up-regulated in both CD4+ (Figure 2C) and CD8+ T cells (Figure 3C) of the patients. The data demonstrated a weak activation of CD4+ T cells, but a strong activation of CD8+ T cells during SARS-CoV-2 infection.

3.3 An increase in germinal centre-like cells in COVID-19 patients

T follicular helper (Tfh) cells help in activation of B cells and differentiation into effector cells, production of high-affinity antibodies and formation of germinal centres. To study whether COVID-19 patients produced efficient adaptive immune response, we analysed the expression of PD-1 and CXCR5 in CD4+ T cells and the expression of Fas and GL7 in B cells. As shown in Figure 4A and B, there was a significant increase in Tfh-
3.4 | Correlation analysis between activation signature and patient age

To study whether age affects adaptive immune cell populations and effector features, we performed correlation analysis between T cell activation markers and age. No dramatic change was observed with increase in age of the patients (Figure 5). The results indicate that there was no defect in CD8^+ T cell activation and Tfh- and GCB-like cell differentiation in the aged individuals infected by SARS-CoV-2.
from COVID-19 remain poorly established, especially in mild or moderate patients. In accordance with several previous reports, our results revealed that patients with mild or moderate symptoms were shown to have an apparent increase in follicular helper CD4 T cells (TFH) and germinal centre B (GCB) cells, while severe COVID-19 patients displayed dysregulation of lymphocytes characterized by a profound depletion of CD4⁺ lymphocytes and subsequently B cell lymphopenia. Also, Wen and colleagues utilized single-cell RNA sequencing to demonstrate that both CD4⁺ and CD8⁺ T cells decreased remarkably, whereas the B cells underwent a significant increase during the recovery phase of COVID-19. Furthermore, Zhang et al developed an immune response phenotyping strategy based on neutrophil-to-lymphocyte ratio (NLR) and IgG level to stratify patients with varying disease severities and outcome, which would be helpful to guide treatment options in the clinic. Collectively, these studies provide a first glimpse into the phenotypes of T and B cell subsets associated with COVID-19. However, the relevant conclusions need to be interpreted with caution due to the limited number of patients enrolled in these studies. Therefore, further investigation is needed to better determine the phenotype and function of T and B cell subsets in COVID-19 patients.

Lymphopenia was observed in COVID patients in previous studies. Epidemiological investigation of coronavirus infection showed that lymphopenia is present in more than 80% of the patients, and serious decline in lymphocytes is correlated with a poor prognosis. However, we did not observe a significant decrease in lymphocyte populations in the COVID-19 patients. This finding could be attributed to the fact that most of the patients in this study showed mild symptoms besides fever. Interestingly, following the division of patients into symptomatic and asymptomatic, we observed a decrease in lymphocytes in the symptomatic patients (data not shown). PD-1 is a marker of exhausted T cells during chronic and acute infections. A number of studies have shown that PD-1⁺ CD8⁺ T cells increase in the peripheral blood of patients with a variety of acute viral infections, such as HBV, HIV and Ebola virus. In our study, the expression of PD-1 was up-regulated in both CD4⁺ and CD8⁺ T cells of COVID-19 patients, which may explain the observed reduction in the lymphocyte population.

In response to viral infections, normally both CD4⁺ and CD8⁺ T cells become activated. In COVID-19 patients, we observed mild activation of CD4⁺ T cells but stronger activation of CD8⁺ T cells based on CD25 expression. This reflects that CD8⁺ cells are major responders of COVID-19 infection and are consistently activated. It is possible that CD4⁺ T cells may be strongly activated earlier during the infection and then revert to the quiescent state after providing helper functions, which could explain the undetected activated phenotype. This could be explained by the comparable expression of CD69, an early activation marker, in HDs and patients. CD4⁺ T cells may indeed be weakly activated in response to the virus, which warrants further studies.

During viral infections, the antigen-specific immune response is executed by Tfh and GCB cells. Tfh cells help B cell differentiate into

**FIGURE 4** Increase of germinal centre-like cells in COVID-19 patients. (A) The percentage of PD-1⁺CXCR5⁺ cells in CD4⁺ T cells. (B) The percentage of Fas⁺GL7⁺ cells in B cells. Each dot represents a single patient of COVID-19 or healthy donor. *P<0.05 and **P<0.01 were considered statistically significant and extremely significant, respectively.

**FIGURE 5** Correlation analysis between functional signature and patient age. The correlation analysis between patient age and immune parameters was performed using Pearson’s correlation coefficient. The percentage of total lymphocytes (A), B cells (B), CD8⁺CD25⁺ T cells (C), CD8⁺PD-1⁺ T cells (D), Tfh-like cells (E) and GCB-like cells (F) was correlated with age in COVID-19 patient group. Each dot represents a single patient of COVID-19 or healthy donor. Patients under the age of 15 years were excluded.
antigen-specific effector cells to produce high-affinity antibodies and facilitate GC formation, which are essential for inducing efficient virus clearance. In COVID-19 patients, there was an increase in both Tfh- and GBC-like cells in the blood, which reflected that an antigen-specific response can be activated upon SARS-CoV-2 infection.

Elderly individuals typically exhibit a reduction in the lymphocyte populations and a weaker ability to defend against viral infections. In our correlation analysis, we did not observe a significant correlation between lymphocyte proportions, effector features and age. Our data suggest that the specific populations of T and B cells for SARS-CoV-2 are reserved in aged individuals; this needs to be proven by repertoire sequencing analysis of T cell and B cell receptors in elderly patients.

In summary, our study shows that SARS-CoV-2 could induce relatively normal adaptive immune response in patients. Most people across different age groups are capable of mobilizing the adaptive immune cells, and activating cellular and humoral immunity to defend against the virus with sufficient medical care and anti-viral treatment.

ACKNOWLEDGEMENTS
This manuscript has been released as a pre-print at [https://doi.org/10.1101/2020.03.23.20040675], (Yang et al.).

CONFLICT OF INTEREST
We declare no competing interests.

AUTHORS’ CONTRIBUTIONS
Xiaofeng Yang, Xiaobo Zhou, Lei Lei, Xingzhe Zhang and Dan Zhang: Data analysis and writing of the manuscript. Tongxin Dai, Hongbo Qian, Rui Guo and Yaling Guo: Sample collection and information. Lin Shi and Yanbin Cheng: Data analysis discussion. Jinsong Hu: FCAS analysis. Baojun Zhang: Generation of idea, experiment design and writing of the manuscript. All authors agree to be responsible for their own part of the work. Xiaofeng Yang: Data curation (lead). Tongxin Dai: Data curation (lead). Xiaobo Zhou: Data curation (equal). Hongbo Qian: Data curation (equal). Rui Guo: Data curation (equal). Lei Lei: Data curation (equal). Xingzhe Zhang: Data curation (equal). Dan Zhang: Data curation (equal). Lin Shi: Formal analysis (equal). Yanbin Cheng: Formal analysis (equal). Jinsong Hu: Methodology (lead). Yaling Guo: Data curation (lead). Baojun Zhang: Project administration (lead); Writing-review & editing (lead).

DATA AVAILABILITY STATEMENT
All data, models and code generated or used during the study are available in the submitted article.

ORCID
Xiaofeng Yang https://orcid.org/0000-0002-2832-0597
Lei Lei https://orcid.org/0000-0002-7506-2180
Jinsong Hu https://orcid.org/0000-0003-0565-4567
Baojun Zhang https://orcid.org/0000-0002-7786-4304

REFERENCES
1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
3. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
4. Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The middle east respiratory syndrome (MERS). Infect Dis Clin North Am. 2019;33(4):891–905.
5. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoVs. Viruses. 2020;12(2):135.
6. Lu R, Zhao X, Li J, et al. Anemia and thrombocytopenia in COVID-19 patients: a report from Wuhan, China. Clinicoepidemiol. 2020;12:1839–1846. 2020;12:1839–1846.
7. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med. 2020;382(8):727–733.
8. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. BMJ. 2003;326(7403):1358–1362.
9. Li T, Qiu Z, Zhang L, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189(4):648–651.
10. Caruso A, Licenziati S, Corulli M, et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry. 1997;27(1):71–76.
11. Gonzalez-Amaro R, Cortes JR, Sanchez-Madrid F, Martin P. Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med. 2013;19(10):625–632.
12. Cai C, Zeng X, Ou AH, Huang Y, Zhang X. Study on T cell subsets and their activated molecules from the convalescent SARS patients during two follow-up surveys. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2004;20(3):322–324.
13. Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect. 2012;1(9):e23.
14. Liu SA, Dai WS, Zhang JP, et al. The study of T lymphocyte in severe acute respiratory syndrome (SARS). Chinese Journal of Immunology. 2003;19(6):375–380.
15. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–761.
16. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
17. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
18. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
19. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–462.
20. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e973.
21. Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6:31.
22. Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–775.
23. Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature*. 2020;584(7821):443–449.

24. Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. *Trends Immunol*. 2015;36(7):410–418.

25. Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for C. clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–1720.

26. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe*. 2020;27(6):992–1000. e1003.

27. Zhang BC, Zhou XY, Zhu CL, Song YX, Feng F, Qiu YR, Feng J, Jia QZ, Song QB, Zhu B, Wang J. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. *Front Mol Biosci*. Posted March 16, 2020. 2020;7(157). https://doi.org/10.1101/2020.03.12.20035048

28. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current state of the science. *Immunity*. 2020, 52(6): 910–941.

29. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. 2020;5(1): 33. https://doi.org/10.1038/s41392-020-0148-4

30. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol*. 2009;10(1):29–37.

31. Santamaria MF, Chen L. A Paradigm shift in cancer immunotherapy: From enhancement to normalization. *Cell*. 2018;175(2):313–326.

32. Schonrich G, Raftery MJ. The PD-1/PD-L1 axis and virus infections: A delicate balance. *Front Cell Infect Microbiol*. 2019;9:207.

33. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. *Proc Natl Acad Sci USA*. 2015;112(15):4719–4724.

34. Palmer S, Albergante L, Blackburn CC, Newman TJ. Thymic involution and rising disease incidence with age. *Proc Natl Acad Sci USA*. 2018;115(8):1883–1888.

35. Yang XF, Dai TX, Zhou XB et al. Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2. *medRxiv*. 2020. https://doi.org/10.1101/2020.03.23.20040675

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Yang X, Dai T, Zhou X, et al. Naturally activated adaptive immunity in COVID-19 patients. *J Cell Mol Med*. 2020;24:12457–12463. [https://doi.org/10.1111/jcmm.15771](https://doi.org/10.1111/jcmm.15771)